In this video, Jacqueline Cloos, PhD, Amsterdam UMC, Amsterdam, The Netherlands, shares some insights into the prognostic impact of CD34+CD38- leukemic stem cells (LSCs) in patients with acute myeloid leukemia (AML) observed in the HOVON-SAKK-132 trial (EudraCT 2013-002843-2). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.